With all this preparedness, what have we forgotten?

Frederick M. Burkle, Jr., MD, MPH, DTM, FAAP, FACEP
Senior Public Policy Scholar, Woodrow Wilson International Center for Scholars
Senior Fellow, Harvard Humanitarian Initiative

This icon indicates sessions that will be webcast live on December 2 and 3 and archived on www.MedicalCountermeasures.gov in January 2010.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Location</th>
<th>Moderator/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 – 10:45</td>
<td><strong>Break in the Marriott Salon Lobby</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45 – 11:15</td>
<td><strong>Moderator: Robin A. Robinson, PhD</strong></td>
<td>Marriott Salons II &amp; III</td>
<td>Deputy Assistant Secretary, Office of Preparedness and Response</td>
</tr>
<tr>
<td></td>
<td><strong>Director, Biomedical Advanced Research and Development Authority</strong></td>
<td></td>
<td>U.S. Department of Health and Human Services</td>
</tr>
<tr>
<td></td>
<td><strong>HHS / AMA JOINT SESSION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PANEL: Environmental Monitoring and Human Health Surveillance</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Early Detection</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Robert R. Hooks</strong></td>
<td></td>
<td>Deputy Assistant Secretary for Weapons of Mass Destruction and Biodefense</td>
</tr>
<tr>
<td></td>
<td><strong>Office of Health Affairs</strong></td>
<td></td>
<td>U.S. Department of Homeland Security</td>
</tr>
<tr>
<td></td>
<td><strong>Human Health Surveillance and Public Health Biometrics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Daniel Sosin, MD, MPH, FACP</strong></td>
<td></td>
<td>Captain, U.S. Public Health Service</td>
</tr>
<tr>
<td></td>
<td><strong>Acting Director, Coordinating Office for Terrorism Preparedness and Emergency Response</strong></td>
<td></td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td></td>
<td><strong>U.S. Department of Health and Human Services</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 – 11:45</td>
<td><strong>HHS / AMA JOINT SESSION</strong></td>
<td>Marriott Salons II &amp; III</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PANEL: The Role of Public Health Laboratories and Clinical Diagnostics in Medical Countermeasure Preparedness</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Laboratory Response Network</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Lisa D. Rotz, MD, FIDSA</strong></td>
<td></td>
<td>Director, Division of Bioterrorism Preparedness and Response</td>
</tr>
<tr>
<td></td>
<td><strong>National Center for Preparedness, Detection, and Control of Infectious Diseases</strong></td>
<td></td>
<td>U.S. Department of Health and Human Services</td>
</tr>
<tr>
<td></td>
<td><strong>Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Association of Public Health Laboratories</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Peter A. Shult, PhD</strong></td>
<td></td>
<td>Director, Communicable Disease Division and Emergency Laboratory Response</td>
</tr>
<tr>
<td></td>
<td><strong>Wisconsin State Laboratory of Hygiene</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45 – 12:00</td>
<td><strong>HHS / AMA JOINT SESSION</strong></td>
<td>Marriott Salons II &amp; III</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Medical Countermeasures in Federal Public Health Emergency Response Plans</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Kevin Yeskey, MD</strong></td>
<td></td>
<td>Deputy Assistant Secretary, Office of Preparedness and Response</td>
</tr>
<tr>
<td></td>
<td><strong>Director, Office of Preparedness and Emergency Operations</strong></td>
<td></td>
<td>U.S. Department of Health and Human Services</td>
</tr>
<tr>
<td>12:00 – 12:15</td>
<td><strong>HHS / AMA JOINT SESSION</strong></td>
<td>Marriott Salons II &amp; III</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>The Strategic National Stockpile of Public Health Emergency Medical Countermeasures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Greg Burel</strong></td>
<td></td>
<td>Director, Division of Strategic National Stockpile</td>
</tr>
<tr>
<td></td>
<td><strong>Coordinating Office for Terrorism Preparedness and Emergency Response</strong></td>
<td></td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td></td>
<td><strong>U.S. Department of Health and Human Services</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15 – 1:30</td>
<td><strong>Lunch On Your Own</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Discussion Session</td>
<td>Host</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>1:30 – 3:15</td>
<td><strong>PHEMCE Stakeholders Breakout Discussion Sessions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virginina A</td>
<td><strong>Priority-Setting for the Public Health Emergency Medical Countermeasures Enterprise</strong></td>
<td><strong>Host:</strong> Michael Mair, MPH&lt;br&gt;Program Analyst; Policy, Planning, and Requirements Division&lt;br&gt;Biomedical Advanced Research and Development Authority&lt;br&gt;Office of the Assistant Secretary for Preparedness and Response&lt;br&gt;U.S. Department of Health and Human Services</td>
<td></td>
</tr>
<tr>
<td>Virginina B</td>
<td><strong>Regulatory Issues</strong></td>
<td><strong>Host:</strong> Debra A. Yeskey, PharmD&lt;br&gt;Director, Regulatory and Quality Affairs Division&lt;br&gt;Biomedical Advanced Research and Development Authority&lt;br&gt;Office of the Assistant Secretary for Preparedness and Response&lt;br&gt;U.S. Department of Health and Human Services</td>
<td></td>
</tr>
<tr>
<td>Virginina C</td>
<td><strong>The Role of the Public in Public Health Preparedness</strong></td>
<td><strong>Hosts:</strong> Elin Gursky, ScD, MSc and Julie Hantman, MPH&lt;br&gt;Policy, Planning, and Requirements Division&lt;br&gt;Biomedical Advanced Research and Development Authority&lt;br&gt;Office of the Assistant Secretary for Preparedness and Response&lt;br&gt;U.S. Department of Health and Human Services</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td><strong>Building and Sustaining Medical Countermeasure Industries for CBRN Threats and Pandemic Influenza</strong></td>
<td><strong>Host:</strong> Gerald R. Kovacs, PhD&lt;br&gt;Director, CBRN Countermeasures&lt;br&gt;Biomedical Advanced Research and Development Authority&lt;br&gt;Office of the Assistant Secretary for Preparedness and Response&lt;br&gt;U.S. Department of Health and Human Services</td>
<td></td>
</tr>
<tr>
<td>Wilson A</td>
<td><strong>Community Preparedness for All-Hazards Response: Planning for Vulnerable Populations</strong></td>
<td><strong>Host:</strong> Todd Lennon, LCSW&lt;br&gt;Lieutenant Commander, U.S. Public Health Service&lt;br&gt;Team Lead for Operations&lt;br&gt;Office for At-Risk Individuals, Behavioral Health, and Human Services Coordination&lt;br&gt;Office of the Assistant Secretary for Preparedness and Response&lt;br&gt;U.S. Department of Health and Human Services</td>
<td></td>
</tr>
<tr>
<td>Wilson B</td>
<td><strong>National Health Security Strategy</strong></td>
<td><strong>Host:</strong> Matthew Minson, MD&lt;br&gt;Senior Medical Officer for Strategic Initiatives&lt;br&gt;Office of Policy, Strategic Planning, and Communications&lt;br&gt;Office of the Assistant Secretary for Preparedness and Response&lt;br&gt;U.S. Department of Health and Human Services</td>
<td></td>
</tr>
<tr>
<td>Wilson C</td>
<td><strong>Performance Measures for Medical Countermeasure Distribution and Utilization in Public Health Emergency Response</strong></td>
<td><strong>Host:</strong> Stephanie M. Dulin, MBA&lt;br&gt;Chief, Program Preparedness Branch&lt;br&gt;Division of Strategic National Stockpile&lt;br&gt;Coordinating Office for Terrorism Preparedness and Emergency Response&lt;br&gt;Centers for Disease Control and Prevention&lt;br&gt;U.S. Department of Health and Human Services</td>
<td></td>
</tr>
</tbody>
</table>
3:15 – 3:30  Break in the Marriott Salon Lobby

3:30 – 4:15  Marriott Salon II

Moderator: RADM Ann Knebel, RN, DNSc, FAAN
Deputy Director for Preparedness Planning
Office of Preparedness and Emergency Operations
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

PANEL: State, Local, Tribal, and Territorial Medical Countermeasure Dispensing – Best Practice Examples

Dana Carey
Strategic National Stockpile Coordinator
Yolo County (California) Health Department

David L. Lakey, MD
Commissioner
Texas Department of State Health Services

Linda Scott, BSN, MA, CIC
Bioterrorism Hospital Preparedness Program Coordinator
Michigan Department of Community Health

4:15 – 5:00  Marriott Salon II

PANEL: Maximizing Resources in a Public Health Emergency Response

Medical Surge Capacity
Sally J. Phillips, RN, PhD
Director, Public Health Emergency Preparedness Research Program
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services

The Hospital Preparedness Program
Gregg Pane, MD
Director, National Healthcare Preparedness Program
Office of Preparedness and Emergency Operations
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

Allocation of Scarce Resources
C. Norman Coleman, MD
Senior Investigator and Head, Experimental Therapeutics Section, Center for Cancer Research
Radiation Oncology Branch, National Cancer Institute, National Institutes of Health
Senior Medical Advisor and Chief of the CBRN Team
Office of Mass Casualty Planning, Office of Preparedness and Emergency Operations
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

5:00 – 6:00  HHS / AMA JOINT EVENT
Reception and Poster Session – Exhibit Hall A

HHS PHEMCE Stakeholders Workshop 2009 & BARDA Industry Day
Medical Countermeasures: From The Bench to The Bloodstream
Thursday, December 3, 2009
Washington Marriott Wardman Park
Washington, DC

Medical Countermeasures: From the Bench to the Bloodstream

Thursday December 3
8:30 – 9:00
Marriott Salons II & III

HHS / AMA JOINT SESSION
Opening Remarks

Invited: Regina M. Benjamin, MD, MBA
Surgeon General
Vice Admiral, United States Public Health Service
U.S. Department of Health and Human Services

9:00 – 10:15
Marriott Salons II & III

HHS / AMA JOINT SESSION
The Future of the PHEMCE

Opening Remarks
Nicole Lurie, MD, MSPH
Rear Admiral, U.S. Public Health Service
Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

Robin A. Robinson, PhD
Deputy Assistant Secretary, Office of Preparedness and Response
Director, Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Boris D. Lushniak, MD, MPH
Assistant Surgeon General and Rear Admiral, United States Public Health Service
Assistant Commissioner, Counterterrorism Policy
Office of Counterterrorism and Emerging Threats
Office of the Commissioner, Food and Drug Administration
U.S. Department of Health and Human Services

Daniel M. Sosin, MD, MPH, FACP
Captain, U.S. Public Health Service
Acting Director, Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

Carol A. Heilman, PhD
Director, Division of Microbiology and Infectious Disease
National Institute of Allergy and Infectious Disease
National Institutes of Health
U.S. Department of Health and Human Services
10:15 – 10:30  Break in the Marriott Salon Lobby

10:30 – 10:45  Marriott Salon II

Moderator: Carol D. Linden, PhD
Principal Deputy Director
Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

Case Study of Anthrax Medical Countermeasure Preparedness and Response

Thomas F. MacKay
Senior Program Analyst
Training, Exercises, and Lessons Learned
Office of Preparedness and Emergency Operations
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

10:45 – 11:45  Marriott Salon II

PANEL: The PHEMCE Process of Developing Medical Countermeasures

Establishing Medical Countermeasure Policy and Requirements
Monique K. Mansoura, PhD
Director, Medical Countermeasure Policy, Planning, and Requirements Division
Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

An Integrated Portfolio Approach
Carol D. Linden, PhD
Principal Deputy Director
Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

Basic Medical Countermeasure Research
Michael G. Kurilla, MD, PhD
Director, Office of BioDefense Research Affairs
Associate Director for BioDefense Product Development
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
U.S. Department of Health and Human Services

Supporting Advanced Development
Gerald R. Kovacs, PhD
Director, CBRN Countermeasures
Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

11:45 – 11:50  Marriott Salon II

Anthrax Case Study Update #1
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Moderator/Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50 – 12:05</td>
<td>Regulatory Issues for Public Health Emergency Medical Countermeasures</td>
<td>Boris D. Lushniak, MD, MPH &lt;br&gt;Assistant Surgeon General and Rear Admiral, United States Public Health Service &lt;br&gt;Assistant Commissioner, Counterterrorism Policy; Office of Counterterrorism and Emerging Threats &lt;br&gt;Office of the Commissioner, Food and Drug Administration &lt;br&gt;U.S. Department of Health and Human Services</td>
</tr>
<tr>
<td>12:05 – 12:10</td>
<td>Anthrax Case Study Update #2</td>
<td></td>
</tr>
<tr>
<td>12:10 – 1:40</td>
<td>Lunch On Your Own</td>
<td></td>
</tr>
<tr>
<td>1:40 – 2:15</td>
<td>PANEL: Q &amp; A with the FDA</td>
<td>Moderator: Boris D. Lushniak, MD, MPH &lt;br&gt;Assistant Surgeon General and Rear Admiral, United States Public Health Service &lt;br&gt;Assistant Commissioner, Counterterrorism Policy; Office of Counterterrorism and Emerging Threats &lt;br&gt;Office of the Commissioner, Food and Drug Administration &lt;br&gt;U.S. Department of Health and Human Services &lt;br&gt;Sally A. Hojvat, PhD &lt;br&gt;Director, Division of Microbiology Devices; Office of In-vitro Diagnostic Device Evaluation and Safety &lt;br&gt;Center for Devices and Radiological Health (CDRH), Food and Drug Administration &lt;br&gt;U.S. Department of Health and Human Services &lt;br&gt;Cynthia L. Kelley, MS &lt;br&gt;Senior Advisor for Counterterrorism and Medical Countermeasures; Office of the Director &lt;br&gt;Center for Biologics Evaluation and Research (CBER), Food and Drug Administration &lt;br&gt;U.S. Department of Health and Human Services &lt;br&gt;Rosemary Roberts, MD &lt;br&gt;Director, Office of Counterterrorism and Pediatric Drug Development &lt;br&gt;Center for Drug Evaluation and Research (CDER), Food and Drug Administration &lt;br&gt;U.S. Department of Health and Human Services</td>
</tr>
<tr>
<td>2:15 – 2:20</td>
<td>Anthrax Case Study Update #3</td>
<td></td>
</tr>
<tr>
<td>2:20 – 2:50</td>
<td>PANEL: Medical Countermeasure Dispensing Issues</td>
<td>Moderator: Carol D. Linden, PhD &lt;br&gt;Principal Deputy Director; Biomedical Advanced Research and Development Authority &lt;br&gt;Office of the Assistant Secretary for Preparedness and Response &lt;br&gt;U.S. Department of Health and Human Services</td>
</tr>
<tr>
<td></td>
<td>Assessing Dispensing Preparedness</td>
<td>Stephanie M. Dulin, MBA &lt;br&gt;Chief, Program Preparedness Branch; Division of Strategic National Stockpile &lt;br&gt;Coordinating Office for Terrorism Preparedness and Emergency Response &lt;br&gt;Centers for Disease Control and Prevention &lt;br&gt;U.S. Department of Health and Human Services</td>
</tr>
<tr>
<td></td>
<td>PREP Act Liability Coverage</td>
<td>Susan Sherman, JD, MHS &lt;br&gt;Office of the General Counsel &lt;br&gt;U.S. Department of Health and Human Services</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Speaker</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2:50 – 2:55</td>
<td>Anthrax Case Study Update #4</td>
<td></td>
</tr>
<tr>
<td>2:55 – 3:15</td>
<td>Novel Medical Countermeasure Dispensing Modalities</td>
<td>Matthew Minson, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Senior Medical Officer for Strategic Initiatives</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Office of Policy, Strategic Planning, and Communications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Office of the Assistant Secretary for Preparedness and Response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>U.S. Department of Health and Human Services</td>
</tr>
<tr>
<td>3:15 – 3:20</td>
<td>Anthrax Case Study Update #5</td>
<td></td>
</tr>
<tr>
<td>3:20 – 3:35</td>
<td>Break in Marriott Salon Lobby</td>
<td></td>
</tr>
<tr>
<td>3:35 – 4:25</td>
<td>Reports from Break-Out Discussion Sessions</td>
<td></td>
</tr>
<tr>
<td>4:25 – 4:35</td>
<td>Anthrax Case Study Conclusion</td>
<td>Thomas F. MacKay</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Senior Program Analyst; Training, Exercises, and Lessons Learned</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Office of Preparedness and Emergency Operations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Office of the Assistant Secretary for Preparedness and Response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>U.S. Department of Health and Human Services</td>
</tr>
<tr>
<td>4:35 – 5:00</td>
<td>Workshop Summary and Closing</td>
<td></td>
</tr>
<tr>
<td>5:00 – 6:00</td>
<td>Reception and Poster Session – Exhibit Hall A</td>
<td></td>
</tr>
</tbody>
</table>

This icon indicates sessions that will be webcast live on December 2 and 3 and archived on [www.MedicalCountermeasures.gov](http://www.MedicalCountermeasures.gov) in January 2010.
## VACCINES
**Washington Room 4**

**Moderator:** Narayan Iyer, PhD  
Acting Chief, Anthrax Vaccines Section  
Division of CBRN Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

### 9:00 – 10:08
**Vaccine Plenary Session:**  
**Potency Assay Development**

**Juan L. Arciniega, DSc**  
Laboratory of Methods Development and Quality Control  
Office of Vaccines Research and Review  
Center for Biologics Evaluation and Research  
Food and Drug Administration  
U.S. Department of Health and Human Services

### 9:00 – 9:22
**ARA 290, a Promising Post-Exposure Radiomitigant for the Gastrointestinal and Hematopoietic Syndromes of the Acute Radiation Syndrome**

**Anthony Cerami**  
Araim Pharmaceuticals, Inc.

### 9:23 – 9:45
**Rx10X and EDL2000: Two Novel Classes of Radioprotectants and Radiomitigators**

**Gabor Tigyi**  
RxBio, Inc.

### 9:46 – 10:08
**Mesenchymal Stem Cell-Based Antioxidant Gene Therapy For Radiation Injuries**

**Weiwen Deng**  
Spectrum Health

### 10:09 – 10:30
**Development of a Highly Stable Lyophilized rPA Based Anthrax Vaccine**

**Matthew Duchars**  
PharmAthene

---

## THERAPEUTICS
**Washington Room 5**

**Moderator:** Ronald G. Manning, PhD  
Chief  
Chemical, Radiological & Nuclear Medical Countermeasures  
Division of CBRN Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

### 9:00 – 9:22
**ARA 290, a Promising Post-Exposure Radiomitigant for the Gastrointestinal and Hematopoietic Syndromes of the Acute Radiation Syndrome**

**Anthony Cerami**  
Araim Pharmaceuticals, Inc.

### 9:23 – 9:45
**Rx10X and EDL2000: Two Novel Classes of Radioprotectants and Radiomitigators**

**Gabor Tigyi**  
RxBio, Inc.

### 9:46 – 10:08
**Mesenchymal Stem Cell-Based Antioxidant Gene Therapy For Radiation Injuries**

**Weiwen Deng**  
Spectrum Health

### 10:09 – 10:30
**Development of a Highly Stable Lyophilized rPA Based Anthrax Vaccine**

**Matthew Duchars**  
PharmAthene

---

## PLATFORM TECHNOLOGIES
**Washington Room 6**

**Moderator:** Dawn Myscofski, PhD, MBA  
Chief, Smallpox Vaccines and Therapeutics  
Division of CBRN Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

### 9:00 – 9:22
**Rapid and Efficient Immunization Against Pandemic Flu or Agents of Bioterrorism via 3M’s Microstructured Transdermal System**

**Kris Hansen**  
3M Drug Delivery Systems

### 9:23 – 9:45
**Human Antibodies for the Treatment of Pandemic Influenza Isolated with a Novel Platform Technology Reveal a Broadly Protective Epitope that is Highly Conserved Among Human and Non-Human Influenza A Viruses**

**Jennifer Mitcham**  
Theraclone Sciences

### 9:46 – 10:08
**Development of an Aerosol Model for the Assessment of Vaccines and or Antivirals to Smallpox**

**Simon Funnell**  
Health Protection Agency  
Centre for Emergency Preparedness and Response, UK

### 10:09 – 10:30
**A Broadly Applicable Stabilisation Technology for Vaccines and Biopharmaceuticals**

**Jefferey Drew**  
Stabilitech, Ltd.
### VACCINES
**Washington Room 4**

**Moderator:** Phil Ferro PhD, MS  
Chief of Portfolio Management  
Division of CBRN Countermeasures  
Biomedical Advanced Research and Development Authority  
Office of the Assistant Secretary for Preparedness and Response  
U.S. Department of Health and Human Services

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Presenter</th>
<th>Company/Institution</th>
</tr>
</thead>
</table>
| 10:50 – 11:12 | LC16m8, an Attenuated Smallpox Vaccine Will Become an Effective Countermeasure against Bio-terrorism with Smallpox Virus | Hiroyuki Yokote  
Kaketsukken |                               |

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Presenter</th>
<th>Company/Institution</th>
</tr>
</thead>
</table>
| 11:13 – 11:35 | Establishing Industrial Scale Manufacturing for IMVAMUNE®, a Safe Smallpox Vaccine – in Collaboration with BARDA | Anders Gram  
Bavarian Nordic |                               |

### THERAPEUTICS
**Washington Room 5**

**Moderator:** Ronald G. Manning, PhD  
Chief  
Chemical, Radiological & Nuclear Medical Countermeasures  
Division of CBRN Countermeasures  
Biomedical Advanced Research and Development Authority  
Office of the Assistant Secretary for Preparedness and Response  
U.S. Department of Health and Human Services

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Presenter</th>
<th>Company/Institution</th>
</tr>
</thead>
</table>
| 10:50 – 11:12 | NanoDTPA Oral Zn-DTPA Capsule and Radiation Countermeasures | James Talton  
Nanotherapeutics, Inc. |                               |

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Presenter</th>
<th>Company/Institution</th>
</tr>
</thead>
</table>
| 11:13 – 11:35 | TransCyte An FDA Approved Treatment and Wound Covering for Thermal Burn Wounds | Gary Gentzkow  
Advanced BioHealing |                               |

### PLATFORM TECHNOLOGIES
**Washington Room 6**

**Moderator:** Brian Dattilo, PhD  
Project Officer  
Strategic Science and Technology Division  
Biomedical Advanced Research and Development Authority  
Office of the Assistant Secretary for Preparedness and Response  
U.S. Department of Health and Human Services

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Presenter</th>
<th>Company/Institution</th>
</tr>
</thead>
</table>
| 10:50 – 11:12 | DAS181 Fludase® a Late Phase I Host Targeted Antiviral for All Strains of Influenza Including Pandemic H1N1 – a Clinical and Non-Clinical Update | David Wurtman  
NexBio, Inc. |                               |

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Presenter</th>
<th>Company/Institution</th>
</tr>
</thead>
</table>
| 11:13 – 11:35 | Leukotriene B4 (LTB4) Stimulates Innate Immune Response in Man; A Novel Approach to Prevent and Treat Influenza Infection | Carl-Johan Dalsgaard  
LTB4 Sweden AB |                               |

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Presenter</th>
<th>Company/Institution</th>
</tr>
</thead>
</table>
| 11:36 – 11:59 | Advanced Development of a Pan-filovirus Virus-Like Particle (VLP) Vaccine | Kelly Warfield  
Integrated BioTherapeutics, Inc. |                               |

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Presenter</th>
<th>Company/Institution</th>
</tr>
</thead>
</table>
| 11:36 – 11:59 | Innate Defense Regulators (DRs) Broad-Spectrum Agents with Anti-Inflammatory and Anti-Infective Impact | John North  
Inimex Pharmaceuticals, Inc. |                               |

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Presenter</th>
<th>Company/Institution</th>
</tr>
</thead>
</table>
| 11:36 – 11:59 | Rapid Host Targeted Protection from H1N1 Pandemic Influenza, SARS, VEE, and Other Respiratory Threats | Andres Salazar  
Oncovir, Inc. |                               |

---

**Break 10:30 – 10:50**
### VACCINES  
**Washington Room 4**

**Moderator:** Thomas R. Fuerst, PhD  
Senior Science and Technology Advisor  
Strategic Science and Technology Division  
Biomedical Advanced Research and Development Authority  
Office of the Assistant Secretary for Preparedness and Response  
U.S. Department of Health and Human Services

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 – 1:52</td>
<td>MP-12, a Live Attenuated Virus Vaccine for the Prevention of Rift Valley Fever</td>
<td>George Bettinger</td>
<td>University of Texas Medical Branch</td>
</tr>
<tr>
<td>1:53 – 2:15</td>
<td>ISCOMATRIX® Adjuvant Provides Benefits for Both Seasonal and Pandemic Influenza Vaccines</td>
<td>Steve Rockman</td>
<td>CSL Limited</td>
</tr>
<tr>
<td>2:16 – 2:38</td>
<td>New Platform for Influenza Vaccines</td>
<td>Albert Deisseroth</td>
<td>FDA</td>
</tr>
<tr>
<td>2:39 – 3:01</td>
<td>Rapid, High Capacity Production of Pandemic Influenza Vaccines in <em>E. coli</em></td>
<td>Alan Shaw</td>
<td>VaxInnate Corp.</td>
</tr>
<tr>
<td>3:02 – 3:24</td>
<td>Use of the JVRS-100 Adjuvant for Biothreat Vaccines</td>
<td>Jeff Fairman</td>
<td>Juvaris BioTherapeutics, Inc.</td>
</tr>
</tbody>
</table>

### THERAPEUTICS  
**Washington Room 5**

**Moderator:** Stephen Morris, PhD  
Chief, Antitoxins and Therapeutics  
Division of CBRN Countermeasures  
Biomedical Advanced Research and Development Authority  
Office of the Assistant Secretary for Preparedness and Response  
U.S. Department of Health and Human Services

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 – 1:52</td>
<td>Efficacy of Valortim® in the New Zealand White Rabbit Model for Inhalation Anthrax</td>
<td>Elizabeth Leffel</td>
<td>PharmAthene, Inc.</td>
</tr>
<tr>
<td>2:16 – 2:38</td>
<td>Advanced Development of Anthim (ETI-204), a Highly-Effective Monoclonal Antibody for Treatment of Inhalation Anthrax: Results of Recent Safety and Efficacy Studies</td>
<td>Leslie Casey</td>
<td>Elusys Therapeutics, Inc.</td>
</tr>
<tr>
<td>2:39 – 3:01</td>
<td>The Development of CMX001, a Broad Spectrum Antiviral Drug, for the Prophylaxis and Treatment of Smallpox Infection</td>
<td>Gwendolyn Painter</td>
<td>Chimerix, Inc.</td>
</tr>
</tbody>
</table>

### PLATFORM TECHNOLOGIES  
**Washington Room 6**

**Moderator:** Rodney Wallace  
Chief, CBRN Diagnostics  
Division of CBRN Countermeasures  
Biomedical Advanced Research and Development Authority  
Office of the Assistant Secretary for Preparedness and Response  
U.S. Department of Health and Human Services

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 – 1:52</td>
<td>Advanced Intranasal Delivery Platforms for Liquid and Powder Vaccine Formulations</td>
<td>Timothy Sullivan</td>
<td>Mystic Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>2:39 – 3:01</td>
<td>Commercial Scale Production of Plant Based Proteins</td>
<td>Alex Day</td>
<td>Kentucky BioProcessing, LLC</td>
</tr>
</tbody>
</table>
| 3:02 – 3:24 | Development of a Flexible and Reproducible Aerosol Generation Capability for Use with Select Agents to Allow Medical Countermeasure Testing | Miles Carroll                 | Health Protection Agency  
Centre for Emergency Preparedness and Response, UK |
### DIAGNOSTICS
**Washington Room 4**

**Moderator:** Rodney Wallace  
Chief, CBRN Diagnostics  
Division of CBRN Countermeasures  
Biomedical Advanced Research and Development Authority  
Office of the Assistant Secretary for Preparedness and Response  
U.S. Department of Health and Human Services

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:50 – 4:12</td>
<td>Developing Simple One Step Detectors for Non-Invasive <em>In vitro</em> Screening of Persons Potentially Exposed to Chemical, Biological and Pandemic Influenza Threats</td>
<td>Uma Babu, Rapid Pathogen Screening, Inc.</td>
</tr>
</tbody>
</table>

### THERAPEUTICS
**Washington Room 5**

**Moderator:** Edward Niles, PhD  
Project Officer, Smallpox Therapeutics  
Division of CBRN Countermeasures  
Biomedical Advanced Research and Development Authority  
Office of the Assistant Secretary for Preparedness and Response  
U.S. Department of Health and Human Services

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:50 – 4:12</td>
<td>A Next-Generation Fluoroquinolone as a Broad-Spectrum Countermeasure for the Defeat of Top Priority Bacterial Threat Agents</td>
<td>Michael Eichberg, Achaogen, Inc.</td>
</tr>
</tbody>
</table>

### PLATFORM TECHNOLOGIES
**Washington Room 6**

**Moderator:** Gary L. Disbrow, PhD  
Deputy Director  
Division of CBRN Countermeasures  
Biomedical Advanced Research and Development Authority  
Office of the Assistant Secretary for Preparedness and Response  
U.S. Department of Health and Human Services

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:50 – 4:12</td>
<td>Use of Operations Management Techniques to Model and Manage Catastrophic Epidemiological Events</td>
<td>Mark Abramovich, Interdisciplinary Solutions, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:50 – 4:12</td>
<td>CAdVax Vaccine Platform Provides Nonhuman Primates with 100% Protection against Multi-strain Challenges by Ebola, Marburg, Dengue, and Other Infectious Disease Agents</td>
<td>John Dong, GenPhar, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:13 – 4:35</td>
<td>Calculator for Estimation of Dose from Radiation Exposure: Versions for the Web and Mobile Devices</td>
<td>Judith Bader, National Cancer Institute</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:36 – 4:58</td>
<td>Phase I Dose Escalating Study of Protexia Pegylated Recombinant Butyrycholinesterase for Nerve Agent Prophylaxis in Healthy Volunteers</td>
<td>Valerie Riddle, PharmAthene, Inc.</td>
</tr>
</tbody>
</table>